[Proceedings: Effect of alufibrate (Atherolip) on pyruvate and lipoprotein metabolism in patients with hyperlipidemia type IV].
D000105:Acetyl Coenzyme A / Q000378:metabolism; D000103:Acetyl-CoA Carboxylase / Q000037:antagonists & inhibitors; D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005227:Fatty Acids / Q000096:biosynthesis; D006801:Humans; D006949:Hyperlipidemias / Q000378:metabolism*; D008074:Lipoproteins / Q000378:metabolism*; D008075:Lipoproteins, HDL / Q000378:metabolism; D008077:Lipoproteins, LDL / Q000378:metabolism; D008079:Lipoproteins, VLDL / Q000378:metabolism; D010919:Placebos; D011773:Pyruvates / Q000378:metabolism*
D005227:Fatty Acids; D008074:Lipoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D010919:Placebos; D011773:Pyruvates; D000105:Acetyl Coenzyme A; D000103:Acetyl-CoA Carboxylase; D002994:Clofibrate
Die Wirkung von Alufibrat (Atherolip) auf den Pyruvat- und Lipoproteinstoffwechsel bei Patienten mit Typ-IV-Hyperlipidämie